KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Raw Materials (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Raw Materials for 15 consecutive years, with $21.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Raw Materials fell 8.94% to $21.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $21.9 million, a 8.94% decrease, with the full-year FY2025 number at $21.9 million, down 8.94% from a year prior.
  • Raw Materials was $21.9 million for Q4 2025 at Halozyme Therapeutics, up from $19.0 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $30.6 million in Q3 2024 to a low of $6.0 million in Q1 2021.
  • A 5-year average of $18.2 million and a median of $18.7 million in 2025 define the central range for Raw Materials.
  • Peak YoY movement for Raw Materials: surged 137.5% in 2023, then crashed 37.99% in 2025.
  • Halozyme Therapeutics' Raw Materials stood at $10.7 million in 2021, then grew by 29.24% to $13.8 million in 2022, then surged by 71.45% to $23.6 million in 2023, then rose by 1.56% to $24.0 million in 2024, then fell by 8.94% to $21.9 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Raw Materials are $21.9 million (Q4 2025), $19.0 million (Q3 2025), and $17.8 million (Q2 2025).